FDA clears IND for CER-1236 Phase 1 trial in AML; start expected Q1 2025

CERO THERAPEUTICS HOLDINGS, INC.

FDA cleared CERo's IND for Phase 1 trial of CER-1236 in acute myelogenous leukemia (AML).
Interim CEO Chris Ehrlich said first in-human trial expected to begin Q1 2025.
CER-1236 uses the Chimeric Engulfment Receptor T cell (CER-T) platform targeting hematologic malignancies.
CERo believes CER-T cells may offer broader application than CAR-T, including solid tumors.
Company to deploy resources expeditiously; shares recent program update as key milestone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.